Raloxifene does not influence flow-mediated endothelium-dependent and endothelium-independent vasodilatation of osteopenic postmenopausal women

American Journal of Obstetrics and Gynecology

Volumn 188, Issue 2, 2003, Pages 313-317

  Cagnacci, Angelo ^a   Arangino, Serenella ^a   Renzi, Antonella ^a   Zanni, Anna Lisa ^a   Volpe, Annibale ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Blood flow; Endothelium; Nitric oxide; Raloxifene; Vascular reactivity

Indexed keywords

LOW DENSITY LIPOPROTEIN; PLACEBO; RALOXIFENE;

ADULT; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; BLOOD VESSEL REACTIVITY; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENDOTHELIUM; FEMALE; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; MENOPAUSAL SYNDROME; METABOLISM; OSTEOPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; ULTRASOUND; VASODILATATION;

EID: 0037325216     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2003.83     Document Type: Article

References (25)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative re-analysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 without breast cancer. Lancet 1997;350:1047-59.
2. Mosca L, Collins P, Herrington DM, Mendelsohn ME, Pasternak RC, Robertson RM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001;104:499-503.
3. Clemett D, Spencer CM. Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 2000;60:379-411.
4. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281:2189-97.
5. Clarkson TB. Raloxifene revisited. Fertil Steril 2002;77:445-7.
6. Hishikawa K, Nakaki T, Marumo T, Suzuki H, Kato R, Saruta T. Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett 1995;360:291-3.
7. Imthurn B, Rosselli M, Jager AW, Keller PK, Dubey RK. Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 β-estradiol valerate and cyproterone acetate or medroxy-progesterone acetate. J Clin Endocrinol Metab 1997;82:388-94.
8. Cicinelli E, Ignarro LJ, Matteo MG, Galantino P, Schonauer LM, Falco N. Effects of estrogen replacement on plasma levels of nitric oxide in postmenopausal women. Am J Obstet Gynecol 1999;180:334-9.
9. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilatation in postmenopausal women. Ann Intern Med 1994;121:936-41.
10. Al-Khalili F, Eriksson M, Landgren B-M, Schenk-Gustafsson K. Effect of conjugated estrogen on peripheral flow-mediated vasodilation in postmenopausal women. Am J Cardiol 1998;82:215-8.
11. Bush DE, Jones CE, Bass KM, Walters GK, Bruza JM, Ouyang P. Estrogen replacement reverses endothelial dysfunction in postmenopausal women. Am J Med 1998;104:552-8.
12. Gerhard M, Walsh BW, Tawakol A, Haley EA, Creager SJ, Seely EW, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998;98:1158-63.
13. Vehkavaara S, Hakala-Ala-Pietila T, Virkamaki A, Bergholm R, Ehnholm C, Hovatta O, et al. Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation 2000;102:2687-93.
14. Sorensen KE, Dorup I, Hermann AP, Mosekilde L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998;97:1234-8.
15. Cagnacci A, Modena MG, Malmusi S, Muia N, Volpe A. Effect of prolonged administration of transdermal estradiol on flow-mediated endothelium-dependent and endothelium-independent vasodilation in healthy postmenopausal women. Am J Cardiol 1999;84:367-70.
16. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
17. Gokce N, Keaney JF, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002;105:1567-72.
18. Simoncini T, Genazzani AR. Raloxifene acutely stimulate nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 2000;85:2966-9.
19. Hisamoto K, Ohmichi M, Kanda Y. Induction of nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells. J Biol Chem 2001;276:47642-9.
20. Figtree GA, Lu Y, Webb CM, Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 1999;100:1095-101.
21. Zoma WD, Baker RS, Clark KE. Coronary and uterine vascular responses to raloxifene in the sheep. Am J Obstet Gynecol 2000;182:521-8.
22. Post MS, van der Mooren J, van Baal WM, Neele SJM, Netelenbos JC, Kenemans P. Raloxifene reduces impedance to flow within uterine artery in early postmenopausal women: a 2-year randomized, placebo-controlled, comparative study. Am J Obstet Gynecol 2001;185:557-62.
23. Cerquetani E, Mercuro G, Fini M, Zoncu S, Onorati D, Vitale C, et al. Hormone replacement therapy but not raloxifene improves endothelial function in postmenopausal women with increased cardiovascular risk [abstract]. Menopause 2001;8:453.
24. Saitta A, Altavilla D, Cucinotta D, Morabito N, Frisina N, Corrado F, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001;21:1512-9.
25. Stroes ESG, Koomas HA, de Bruin TWA, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995;346:467-71.